Full Text
EE479 Cost-Effectiveness of Olaparib Compared to Rucaparib for the Treatment of Metastatic Castration-Resistant Prostate Cancer (MCRPC) in United States

Abstract

Authors

P Ghule M Kohli DC Malone RE Nelson

Back to Volume 25, Supplemental Issue 7S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×